Halo Pharma Activates $45M Sterile Injectable Line in New Jersey
- Halo Pharma is bringing online a new sterile injectable manufacturing line at its Whippany, NJ facility, backed by a $45 million investment.
- The platform features a high-speed Groninger filling line and SKAN isolator, with capacity to produce over 50 million units annually and batch sizes from 250–250,000 units.
- The line is undergoing GMP qualification and expected to launch later in 2026, addressing domestic supply-chain capacity constraints for U.S. pharma clients.
Operational Impact
Halo Pharma's new Whippany sterile injectable line adds meaningful domestic fill-finish capacity at a time when the U.S. injectable supply chain is at capacity, offering CDMO buyers an alternative to offshore partners for clinical and commercial batches.
Source: Contract Pharma Breaking News RSS